Adze BioTechnology, Inc. Press Releases

• Published on September 24, 2025 - 13:00 GMT

  

  Adze Biotechnology and King’s College London Announce Clinical Collaboration in hard-to-treat Breast Cancers

  Our goal is to harness the potential of ADZE1.C to reprogram the tumor microenvironment and activate systemic anti-tumor immunity. Dr. Paola Grandi, CSO Adze CORAL GABLES, FL, UNITED STATES, September 24, 2025 /⁨EINPresswire.com⁩/ -- Adze Biotechnology, …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on September 4, 2025 - 16:00 GMT

  

  Adze Biotechnology Secures Bellberry HREC Approval in Australia.

  Adze Biotech, develops systemically-deliverable oncolytic immunotherapies, received Bellberry HREC approval for Phase I clinical trial in metastatic melanoma. CORAL GABLES, FL, UNITED STATES, September 4, 2025 /⁨EINPresswire.com⁩/ -- Adze Biotechnology …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on August 12, 2025 - 05:29 GMT

  

  Adze Biotechnology Submits Bellberry HREC Application for Adze1.C Clinical Trial in Australia

  The Bellberry application is a key regulatory milestone, advancing Adze’s commitment to initiating clinical studies of its immunotherapy candidate, Adze1.C, CORAL GABLES, FLORIDA, UNITED STATES, August 11, 2025 /⁨EINPresswire.com⁩/ -- Adze Biotechnology, …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on January 16, 2025 - 13:30 GMT

  

  ADZE Biotechnology Announces Patent Grant and Notice of Allowance from US Patent and Trademark Office

  The allowed patent application and newly granted patent are part of an expanding intellectual property portfolio directed to the novel adenovirus platform. CORAL GABLES, FL, UNITED STATES, January 16, 2025 /⁨EINPresswire.com⁩/ -- ADZE Biotechnology (ADZE) …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on April 8, 2024 - 12:45 GMT

  

  Paola Grandi, PhD, MBA, Joins Adze Biotechnology to Lead Pre-Clinical and Translational Research Programs.

  ADZE is thrilled to welcome Dr. Paola Grandi to our team as we advance our pipeline of systemically deliverable oncolytic immunotherapies into the clinic. CORAL GABLES, FLORIDA, US, April 8, 2024 /⁨EINPresswire.com⁩/ -- Dr. Paola Grandi, PhD, MBA is the …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on September 14, 2023 - 13:00 GMT

  

  ADZE Biotechnology Reports US Patent Office Grants Patent Claiming Novel Recombinant Adenovirus

  ADZE is a biopharmaceutical company focused on novel cancer therapeutics for a broad range of cancer indications. CORAL GABLES, FLORIDA, US, September 14, 2023 /⁨EINPresswire.com⁩/ -- ADZE Biotechnology Announces Notice of Allowance from US Patent and …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on August 2, 2023 - 13:00 GMT

  

  Adze Biotechnology Announces Members of Scientific Advisory Board

  "The Adze Scientific Advisory Board will provide important counsel in the years ahead, with research & development”, Sidney Hopps, Co-Founder & CEO Adze CORAL GABLES, FLORIDA, US, August 2, 2023 /⁨EINPresswire.com⁩/ -- Adze Biotechnology, Inc …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on March 16, 2023 - 11:00 GMT

  

  Adze Biotechnology Completes $6.2 Million First Closing of Series A Financing

  “This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” - Sidney Hopps, Co-Founder & CEO CORAL GABLES, FLORIDA, US, March 16, 2023 /⁨EINPresswire.com⁩/ -- Coral Gables, March 13, 2023 …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on February 7, 2023 - 15:19 GMT

  

  Adze Biotechnology Announces Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma

  Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers recombinent human CD40 ligand locally into solid tumors. CORAL GABLES, FLORIDA, UNITED STATES, February 7, 2023 /⁨EINPresswire.com⁩/ -- Adze …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on February 1, 2023 - 18:53 GMT

  

  Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform

  The grant of this patent positions Adze to participate in the $18 billion annual checkpoint inhibitor market CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023 /⁨EINPresswire.com⁩/ -- Adze Biotechnology Granted Patent for its Proprietary Oncolytic …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...